Slide 1: Immuron CEO, Steven Lydeamore to present at LD Micro
Immuron CEO, Steven Lydeamore to present at LD Micro Melbourne, Australia, October 4 , 2023 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at th
Slide 2: About Immuron / Forward-looking statements
About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com FORWARD - LOOKING
Slide 3: LD Micro Presentation, 4 October 2023
1 1 LD MICRO PRESENTATION 4 OCTOBER, 2023 S teve n Lyde a m ore - C EO NASDAQ: IMRN ASX: IMC
Slide 4: Forward-looking statements
Certain statements made in this presentation are forward - looking statements and are based on Immuron ’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intend
Slide 5: Executive Summary
EXECUTIVE SUMMARY Company Overview Business Update Results & Outlook • Two commercially available oral immunotherapeutic products – Travelan® and Protectyn® • 4 clinical programs: Travelan®(NMRC: Phase 2 CHIM trial), Travelan®(USU: Phase 4 field study), CampETEC (Phase 2 CHIM trial), IMM - 529 (Prot
Slide 6: Addressable Market & Industry Overview
4 ADDRESSABLE MARKET & INDUSTRY OVERVIEW Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s diarrhoea** $83m Based on US annual travel numbers and a penetration rate of 15%, the market potential is estimated at
Slide 7: Technology Platform
TECHNOLOGY PLATFORM Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full dev
Slide 8: Status of Product Portfolio and Key Milestones
STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES US Department of Defense grant of US$4.45 million to examine a dosing regimen for Travelan® more suited for use by the military • Market evaluation by Lumanity confirms the Traveler’s Diarrhea market opportunity for IMM - 124E (Travelan®) • IMM - 124E (
Slide 9: Key Milestones Anticipated to Drive Value
KEY MILESTONES ANTICIPATED TO DRIVE VALUE • Topline results for IMM - 124E ETEC 2 clinical trial • Clinical Study Report • First patients enrolled • Completion of In - patient phase ETEC 2 CHIM 3 clinical trial • IRB Approval 4 • Initiated IMM - 124E ETEC 2 CHIM 3 clinical trial • FDA IND 1 approved
Slide 10: Immuron's Clinical Programs – Opportunity Assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% p
Slide 11: Distribution Capability
DISTRIBUTION CAPABILITY • The Australian retail network includes over 3,500 pharmacies • In the USA, the key B2B customer is Passport Health - the largest network of travel medicine clinics • Immuron launched its own US shopfront on amazon.com in July 23 • Re - entry into retail pharmacies in USA be
Slide 12: Business Positioned for Organic Growth and New M&A Strategy
BUSINESS POSITIONED FOR ORGANIC GROWTH AND NEW M&A STRATEGY 1. Travelan®: • Sales expansion across target geographies • Growth in distribution network and sales & marketing initiatives • Product development (new formulations including once daily dosing) e.g. FDA approval 1. Protectyn®: • Sales expan
Slide 13: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 11 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 14: Scientific References
1 3 13 SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Researc